The United Kingdom and the United States have agreed to a important trade agreement that will keep zero import taxes on UK pharmaceutical exports going into the American market.
Agreement Details of the Accord
As part of the deal, the UK has pledged to increase expenditure on drugs through the National Health Service (NHS). This commitment ensures that tariffs on these key goods will be held at nothing for a duration of 36 months.
This deal is in response to previous warnings to dramatically increase tariffs on branded drug products, with potential rates floated as high as one hundred percent.
"This deal with the UK reinforces the international landscape for innovative medicines and introduces long-overdue equity to American-British pharmaceutical trade," a release noted.
Trade Impact
Medicines represent one of the Britain's most significant exports to the US, which is easily the biggest destination for large British pharmaceutical firms.
Trade data indicate that in the year to the end of the third quarter, the UK exported drugs worth £11.1bn to the US. This value made up 17.4% of all goods exports in that period.
"This deal protects work, increases funding and paves the way for the UK to establish itself as a international leader for life sciences," a government official commented.
Detailed UK Commitments
The pact involves several key pledges from the UK:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new therapies to be prohibitively costly by 25%.
- Increased NHS Spending: There is a goal to double total NHS spending on drugs from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The percentage manufacturers must pay back to the NHS to control costs will be capped at 15%. Last year, rebates topped twenty percent.
Industry Background
The pact takes place against a protracted tension between the pharmaceutical industry and the ministers over medicine costs and NHS adoption.
This friction were exacerbated by arguments that US patients were charged a premium for the equivalent treatments than consumers in the other developed nations.
Recently, several large drug company projects in the UK have been paused or scrapped, while multi-billion-dollar expansions have been directed toward American operations.
The Science Minister publicly accepted that the NHS had to invest a greater share on treatments, noting that its spending on drugs had decreased as a percentage of its resources over the past decade.
